• 1
    Harris EN. Syndrome of the black swan. Br J Rheumatol 1987; 26: 3246.
  • 2
    Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, Acland R, Harris EN. Effects of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost 1994; 17: 6704.
  • 3
    Pierangeli SS, Liu XW, Anderson GH, Barker JH, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the Antiphospholipid Syndrome. Thromb Haemost 1995; 75: 13617.
  • 4
    Pierangeli SS, Liu X, Anderson GH, Barker JH, Harris EN. Thrombogenic properties of murine anti-cardiolipin antibodies induced by β2glycoprotein 1 and human IgG antiphospholipid antibodies. Circulation 1996; 94: 174651.
  • 5
    Simantov E, LaSala J, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 22119.
  • 6
    Del Papa N, Guidali L, Spatola L, Bonara P, Borghi MO, Tincani A, Balestrieri G, Meroni PL. Relationship between anti-phospholipid and anti-endothelial cell antibodies. β2glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol 1995; 13: 17985.
  • 7
    Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GH, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 19972000.
  • 8
    Gharavi AE, Pierangeli SS, Colden-Stanfield M, Liu XW, Espinola RG, Harris EN. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol 1999; 163: 29227.
  • 9
    Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and P-selectin. Circ Res 2001; 88: 24550.
  • 10
    Wang CR, Liu MF, Tsai RT, Chuang CY, Chen CY. Circulating intercellular adhesion molecules-a and autoantibodies including antiendothelial cells, anti-cardiolipin, and anti-neutrophil cytoplasm antibodies in patients with vasculitis. Clin Rheumatol 1993; 12: 37580.
  • 11
    Kaplanski G, Cacoub P, Farnarier C, Marin V, Gregoire R, Gatel A, Durand JM, Harle JR, Bongrand P, Piette JC. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of the thrombosis. Arthritis Rheum 2000; 43: 5564.
  • 12
    McEver RP. Selectins: novel receptors that mediate leukocyte adhesion during inflammation. Thromb Haemost 1991; 65: 2238.
  • 13
    Read MA, Neish AS, Luscinkas FW, Palombella VJ, Maniatis T. The proteasome pathway is required for cytokien-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995; 2: 493506.
  • 14
    Springer TA. Traffic signals of lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 30110.
  • 15
    Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules. NF kappa B and cytokine-inducible enhancers. FASEB J 1995: 9: 899909.
  • 16
    Read MA, Whitley MZ, Williams AJ, Collins T. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activaiton. J Exp Med 1994; 179: 50312.
  • 17
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193: 26575.
  • 18
    Harris EN. Annotation: antiphospholipid antibodies. Br J Haematol 1990; 74: 19.
  • 19
    Harris EN, Gharavi AE, Patel S, Hughes GRV. Evaluation of the anticardiolipoin antibody test: report of an international workshop held April 4 1986. Clin Exp Immunol 1987; 68: 21522.
  • 20
    Colden-Stanfield M, Ratcliffe D, Cramer EB, Gallin EK. Characterization of influenza virus-induced leukocyte adherence to human umbilical vein endothelial cell monolayers. J Immunol 1993; 151: 31021.
  • 21
    Colden-Stanfield M, Gallin EK. Modulation of K+ currents in monocytes by VCAM-1 and E-selectin on activated human endothelium. Am J Physiol 1998: 275 (Cell Physiol 1998; 44): C26777.
  • 22
    Hall J, Wang X, Van Adamson Zhao Y, Gibbons GH. Over-expression of Ref-1 inhibits hypoxia and tumor necrosis factor-induced endothelial cell apoptosis through nuclear factor kappa-B-independent and-dependent pathways. Circ Res 2001; 88: 124753.
  • 23
    Peter FW, Schuschke DA, Wang WZ, Anderson GH, Franken RJ, Pierangeli S, Barker JH. Do leukocytes contribute to impaired microvascular tissue perfusion after artery repair. Microsurgery 1998; 18: 238.
  • 24
    Liu X, Peter FW, Barker JH, Pierangeli SS, Harris EN, Anderson GL. Leukocyte–endothelium interaction in arterioles after ischemia and reperfusion. J Surg Res 1999; 87: 7784.
  • 25
    George J, Blank M, Levy Y, Meroni P, Damianovich M, Tincani A, Shoenfeld Y. Differential experimental antiphospholipid syndrome. Circulartion 1998; 97: 9006.
  • 26
    Bachman RL, Silverstein RL. Hypercoagulable states. Ann Intern Med 1993; 119: 81927.
  • 27
    Nachman RL, Hajjar KA, Silverstein RL, Dinarello C. IL-1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986; 163: 1595600.
  • 28
    Dobado-Barrios PM, Lopez-Pedrera C, Velasco F, Aguirre Ma Torres AM, Cuadrado MJ. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999; 82: 157882.
  • 29
    Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez JJ, Hughes GRV. Immune mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988; 47: 8546.
  • 30
    Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995; 73: 51924.
  • 31
    Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquie reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002; 87: 51822.
  • 32
    Malia RG, Kitche S, Greaves M, Preston EE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 1017.
  • 33
    Carson CW, Comp PC, Rezaaie AR, Esmon NL, Esmon CT. Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis. J Rheumatol 2000; 27: 38490.
  • 34
    Reverter JC, Tassies D, Font J, Monteagudo J, Escolar G, Ingelmo M, Ordinas A. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vac Biol 1996; 16: 131926.
  • 35
    Ferro D, Pittoni V, Quintarelli C, Basili S, Salioa M, Caroselli C, Valesini G, Violi F. Coexistence of antiphospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with on-going prothrombotic state. Thromb Haemost 1997; 75 (Suppl.): 359.
  • 36
    Meroni PL, Del Papa N, Raschi E, Panzeri P, Borghi MO, Tincani A, Balestrieri G, Khamashta MA, Hughes GRV, Koike T, Krilis SA. β2 glycoprotein I as a ‘co-factor’ for antiphospholipid reactivity with endothelial cells. Lupus 1998; 7: S447.
  • 37
    Del Papa N, Guidali L, Sala A, Buccellatti C, Khamashta MA, Ichikawa K, Koike T, Balestrieri G, Tincani A, Hughes GRV, Meroni PL. Endothelial cell as target for antiphospholipid antibodies. Arthritis Rheum 1997; 40: 55161.
  • 38
    Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A, Khamashta MA, Balestrieri G, Trremoli E, Hess DC. Endothelial activation by aPL: a potential pathogenic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000; 15: 23740.